<- Go Home
LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Market Cap
$252.4M
Volume
764.6K
Cash and Equivalents
$24.8M
EBITDA
-$118.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$19.5M
Profit Margin
92.88%
52 Week High
$50.40
52 Week Low
$6.83
Dividend
N/A
Price / Book Value
1.02
Price / Earnings
-2.20
Price / Tangible Book Value
1.02
Enterprise Value
-$5.3M
Enterprise Value / EBITDA
0.05
Operating Income
-$118.3M
Return on Equity
49.71%
Return on Assets
-31.22
Cash and Short Term Investments
$258.4M
Debt
$673.0K
Equity
$246.5M
Revenue
$21.0M
Unlevered FCF
-$48.8M
Sector
Pharmaceuticals
Category
N/A